FRI0553 The efficacy of 2-years denosumab treatment for glucocorticoid-induced osteoporosis (GIOP). (15th June 2017)

• Record Type: Journal Article
• Authors: Akashi, K; Nishimura, K; Kageyama, G; Ichikawa, S; Shirai, T; Yamamoto, Y; Ichise, Y; Yamada, H; Naka, I; Waki, D; Okano, T; Takahashi, S; Ueda, Y; Sendo, S; Onishi, A; Saegusa, J; Morinobu, A
• Is Part Of: Annals of the rheumatic diseases. Volume 76(2017)Supplement 2
• Page Start: 699
• Page End: 699
• Publication Date: 2017-06-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2017-eular.3050
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Osteoporosis is one of the important adverse effects in the glucocorticoids treatment for the patients with rheumatoid arthritis (RA) and connective tissue diseases (CTDs). Although the usefulness of denosmab for primary osteoporosis has been well-established, the efficacy for GIOP remains unclear. Objectives: This study aimed to clarify the therapeutic effects of denosumab for GIOP. Methods: We evaluated bone mineral density (BMD) and serum markers of bone metabolism (BAP, NTx, TRACP-5b and P1NP) of patients who had been treated with over 5mg of predonisolone for RA and CTDs, and denosumab for GIOP, for two years in Kobe University Hospital. BMD and serum markers were evaluated every six months for 2 years from the baseline. The changes of those data from baseline were analyzed by Student's t test using GraphPad Prism 5 software and p<0.05 was considered statistically significant. Results: Number of the patients were 53 (male: 4 cases, female: 49 cases), and their characteristics at the beginning of denosumab treatment were as below; age: 64.19±12.0 years old, dose of prednisolon: 10.59±9.97mg/day, BMD of lumber spine: 0.768±0.112g/cm 3, T-score of lumber spine: -2.28±1.01, BMD of femoral neck: 0.540±0.085g/cm 3, T-score of femoral neck: -2.28±0.76. After 2-years denosumab treatment, T-scores of lumber spine (0.54±0.39 gain) and femoral neck (0.13±0.26 gain) were significantly increased from baseline (Figure; mean ± SEM. *:p<0.05). In addition, the serum markers of bone metabolism, both absorption and formation, were significantly suppressed with denosumab. Conclusions: Denosumab can suppress bone metabolic turnover, and increase lumber spine and femoral neck T-scores of GIOP patients. Disclosure of Interest: None declared